Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Subsequent Events (Details Narrative)

v3.20.2
Subsequent Events (Details Narrative) - USD ($)
1 Months Ended 12 Months Ended
Jun. 15, 2020
May 10, 2020
May 06, 2020
May 02, 2020
Apr. 24, 2020
Apr. 13, 2020
Apr. 08, 2020
Mar. 23, 2020
Mar. 17, 2020
Feb. 20, 2020
Feb. 13, 2020
Feb. 11, 2020
Feb. 10, 2020
Jan. 02, 2020
Apr. 30, 2020
Mar. 31, 2020
Jan. 31, 2020
May 31, 2019
Dec. 31, 2019
Dec. 31, 2017
May 01, 2020
Stock issued during the period, shares                                   125,000   81,432  
Number of ordinary shares issued, value                                   $ 12,500 $ 295,000    
Ordinary Shares [Member]                                          
Stock issued during the period, shares                                     2,950,000    
Number of ordinary shares issued, value                                     $ 8,429    
Exchange Agreement [Member] | MDM Worldwide Solution, Inc [Member]                                          
Due to related parties, debt                                     1,000,000    
Loan Conversion Agreement [Member]                                          
Due to related parties, debt                                     $ 310,477    
Subsequent Event [Member] | Strategic Global Research and Development, Inc [Member]                                          
Litigation settlement                     $ 91,319                    
Unpaid consulting fees                     71,209                    
Unreimbursed expenses                     $ 20,110                    
Contingencies setllement, interest rate             5.00%                            
Subsequent Event [Member] | Claim Paid Over-Time Per Month [Member] | Strategic Global Research and Development, Inc [Member]                                          
Litigation settlement             $ 4,000                            
Subsequent Event [Member] | Ordinary Shares [Member] | Provista Diagnostics, Inc [Member]                                          
Stock issued during the period, shares                             13,008,976   17,091,096        
Subsequent Event [Member] | Convertible Note Extension Agreements [Member] | Note Warrant [Member] | Third Warrant [Member]                                          
Number of warrants for right to purchase shares                   20,792,380                      
Exercise price of warrants                   $ 0.10                      
Warrants term                   5 years                      
Subsequent Event [Member] | Convertible Note Extension Agreements [Member] | Extended Maturity [Member]                                          
Debt instrument, maturity date                   Aug. 14, 2020                      
Subsequent Event [Member] | Convertible Bridge Loan Agreements [Member]                                          
Number of warrants for right to purchase shares                           24,776,758              
Exercise price of warrants                           $ 0.10              
Warrants term                           5 years              
Debt instrument, face amount                           $ 835,714              
Debt instrument, discount percentage                           30.00%              
Debt Unpaid loan, interest rate                           18.00%              
Repayment of loans, penalty percentage                           20.00%              
Debt instrument, description The Holder is entitled, at its option, at any time, to convert all or any amount of the principal face amount of the Note and the accumulated Interest then outstanding into the Company's ordinary shares at a price equal to 80% of the lower of (i) the lowest closing bid price on the trading day prior to the Issuance Date or (ii) the lowest trading price of the ordinary shares as reported by the trading market on which the Company's shares are traded, for the 20 prior trading days including the day upon which a conversion notice is received (the "Conversion Price"). Upon occurrence of a Sale Event as defined in the Note, the Company shall, upon request of the Holder, redeem the Note in cash in an amount equal to 150% of the principal amount, plus accrued but unpaid interest through the date of redemption, or at the election of the Holder, such Holder may convert the unpaid principal amount of the Note and the unpaid interest into ordinary shares of the Company at the Conversion Price immediately prior to such Sale Event. Upon the occurrence of an Event of Default (as defined in the Note), the Note shall accrue interest at the lower of (i) 24% per annum or (ii) the highest rate of interest permitted by law. In addition, the Company will be subject to the penalty described in paragraph 8 of the Note.                         At the earlier of the effective date of Registration Statement as defined in the Loan Agreements or 6 months after the Effective Date, the Lenders at their sole option, may convert the outstanding Loan Amount, or any portion of the Loan Amount, and any accrued interest, in whole or in part, into shares of the common stock of the Company (the "Common Stock"). Any amount so converted will be converted into common stock of the Company at a price equal to the lower of (1) the closing market price on the date of closing and (2) 50% of the lowest trading price on the primary trading market on which the Company's Common Stock is quoted for the last 10 trading days immediately prior to but not including the Conversion Date ("Conversion Price"). The Lenders shall have a right of participation up to 40% of any future financing (excluding strategic transactions) for a period of 2 years.              
Liquidation damages, value                           $ 12,500              
Liquidation damages, description                           (i) 75 days of the Effective Date or (ii) 30 days after uplisting of the Company's Common Stock to a national securities exchange and / or declared effective within 180 days from the Effective Date of the Loan Agreements, which damages shall accrue each month until the applicable breach (failure to timely file, failure to timely have declared effective, or both) has been cured.              
Debt, principal and interest                           $ 553,973              
Subsequent Event [Member] | Convertible Bridge Loan Agreements [Member] | Loan Amount After Debt Discount [Member]                                          
Debt instrument, face amount                           $ 250,714              
Debt instrument, interest rate                           10.00%              
Subsequent Event [Member] | Convertible Bridge Loan Agreements [Member] | Ordinary Shares [Member]                                          
Debt, conversion of shares                           36,668,926              
Subsequent Event [Member] | Securities Purchase Agreement [Member] | 2% Convertible Redeemable Note [Member]                                          
Debt instrument, maturity date Jun. 15, 2021                                        
Debt instrument, interest rate 2.00%                                        
Debt instrument, description During the first 40 days after the Issuance Date, the Company has the right to redeem the Note at a price equal to 125% of the Note's face amount.                                        
Proceeds from issuance of note $ 315,000                                        
Agreement, description The Company entered into a Securities Purchase Agreement pursuant to which it issued a 2% Convertible Redeemable Note ("Note"). Under the Note, the Company received net cash of $315,000 (which representing 84% of the gross Principal Amount of the note) from a private lender (the "Holder").                                        
Original issue discount percentage 16.00%                                        
Subsequent Event [Member] | Subscription Agreements [Member]                                          
Number of warrants for right to purchase shares                               1,339,284          
Exercise price of warrants                               $ 0.10          
Gross proceeds from issuance of ordinary shares                               $ 30,000          
Stock issued during the period, shares                               1,500,000          
Subsequent Event [Member] | Exchange Agreement [Member] | MDM Worldwide Solution, Inc [Member]                                          
Repayments of debt           $ 100,000                              
Share issuance for exchange of debt           5,000,000                              
Shares exchange, price per share           $ 0.02                              
Subsequent Event [Member] | Letter Agreement [Member] | Toledo Advisors, LLC [Member]                                          
Debt instrument, face amount                                         $ 119,296
Debt, conversion of shares       6,107,026                                  
Debt, conversion price per share                                         $ 0.02
Debt, accrued interest       $ 2,845                                  
Subsequent Event [Member] | Loan Conversion Agreement [Member]                                          
Debt instrument, face amount   $ 350,000                                      
Debt, conversion of shares   8,750,000                                      
Debt, conversion price per share   $ 0.04                                      
Subsequent Event [Member] | Joint Venture Agreement [Member]                                          
Equity ownership percentage, description         Todos Medical USA entered into the Amended and Restated Collaboration Agreement with Emerald, pursuant to which Todos became the owner of 100% of the equity of the Joint Venture (Corona Diagnostics, LLC) and agreed to integrate its COVID-19 tests with Emerald's telemedicine (Carie Health, Inc.) and independent pharmacy business Bonsa Health, Inc. to create a full solution to help facilitate the screening and diagnosis of individuals potentially to identify each indiciation's COVID-19 Polymerase Chain Reaction (PCR) and/or antibody testing status to facilitate return to work programs in the United States.                                
Subsequent Event [Member] | Joint Venture Agreement [Member] | Emerald Organic Products, Inc [Member]                                          
Equity ownership percentage, description               Todos Medical USA entered into Joint Venture Agreement (the "Agreement") with Emerald Organic Products, Inc., a Nevada corporation ("Emerald"), for the formation of Emerald Viral Diagnostics Joint Venture, Inc. (the "Joint Venture") in order to manage, operate and distribute viral testing currently controlled by Todos Medical USA. It was agreed inter alia that (1) Todos Medical USA will contribute diagnostic testing under its control that will be useful in detecting Coronavirus / COVID-19 ("Viral Testing"). Todos Medical USA will contribute the expertise and know-how to the Joint Venture necessary to validate the products for distribution; (2) Emerald will contribute capital for validation as per the budget as described in the Agreement and be responsible for developing and implementing the necessary financial structures for the distribution of the Viral Testing; (3) interest in the Joint Venture shall be 51% owned and controlled by Emerald and 49% owned and controlled by Todos Medical USA; (4) Emerald shall be entitled to receive priority distributions from the Joint Venture up to the amount of any cash capital contributions made by Emerald; (5) the Board of Managers will initially consist of three board members: Two members shall be appointed by Emerald and one member shall be appointed by Todos Medical USA; (6) the Joint Venture shall commence the date hereof and shall continue until the earlier of (i) 25 years or (ii) mutual agreement of Todos Medical USA and Emerald to dissolve.                          
Subsequent Event [Member] | Service Agreements [Member] | Dawson James Securities [Member]                                          
Agreement, description     In consideration for the services to be rendered by Dawson, the Company will pay to Dawson a placement agent fee of 8% of the gross proceeds received in the Offering; provided that such fee will be reduced to 7% for investors introduced to Dawson by the Company. As additional compensation for Dawson's services, the Company shall issue to Dawson or its designees at the closing of the offering ("Closing") warrants (the "Placement Agent's Warrants") to purchase that number of Securities equal to 5% of the aggregate number of securities sold in the offering. The Placement Agent's Warrants will be exercisable at any time and from time to time, in whole or in part, during the five-year period commencing six months from the closing of the offering, at a price per share equal to 125% of the price per Security issued in the offering. The Placement Agent's Warrant will provide for a cashless exercise provision, registration rights (including a one-time demand registration right and unlimited piggyback rights) and customary anti-dilution provisions (for stock dividends and splits and recapitalizations).                                    
Placement agent fee, percentage     8.00%                                    
Subsequent Event [Member] | Service Agreements [Member] | Orion Capital Advisors, LLC [Member] | Restricted Stock [Member]                                          
Stock issued during the period, shares                         2,500,000                
Subsequent Event [Member] | Service Agreements [Member] | AS Iber Israel Ltd [Member]                                          
Debt exchange financing, description                       Success fee equal in amount to 10% plus VAT of the total value of the benefit, monetary or otherwise derived by the Company shall be earned in connection with any other activities as defined in the Agreement, plus 10% in share at the same value as the investment. B. Success fee equal in amount to 7% plus VAT of the total of any success fee earned in connection with any pre and/or post IPO and/or M&A activity whether directly arranged by AS Iber Israel and/or by any registered dealer introduced to the Company by AS Iber Israel who will be entitled to earn this fee in connection with any transaction that is either completed and/or initiated by the registered dealer for a period of 24 months after the initial introduction.                  
Subsequent Event [Member] | Service Agreements [Member] | 3D Biomedicine Science and Technology Co. Limited [Member] | Restricted Stock [Member]                                          
Number of ordinary shares issued, value                 $ 250,000